Hoxworth hospital partner Cincinnati Children's ranks No. 1 children's hospital in the nation
Hoxworth Blood Center, University of Cincinnati, congratulates Cincinnati Children’s Hospital Medical Center on being named as the top children’s hospital in the nation, according to the Best Children's Hospitals rankings for 2023-2024 from U.S. News and World Report.
"We are excited to congratulate and celebrate Cincinnati Children’s on this remarkable, well-deserved honor," said José Cancelas, MD, PhD, Director, Chief Executive Officer, Hoxworth Blood Center, University of Cincinnati. "We are immensely proud of our decades long partnership with Cincinnati Children’s to provide and support exquisite pediatric patient care that is unique to the greater Cincinnati region.”
The Best Children’s Hospitals list also includes national rankings across 10 pediatric specialties. Cincinnati Children’s was named in the top 10 of each of these areas and No. 1 in cancer care, diabetes and endocrinology, neonatology and urology.
As the sole supplier of blood products in the greater Cincinnati region, Hoxworth Blood Center is extremely proud to support Cincinnati Children’s with blood products that directly impact pediatric cancer care, and beyond. More than half of Hoxworth’s platelet collections are directly transfused at Cincinnati Children’s, many of which are used in cancer treatment.
The physicians and researchers at Cincinnati Children’s hold academic appointments at the UC College of Medicine, including Cancelas, where he also leads the stem cell program along with the cancer and blood diseases institute at Cincinnati Children's.
Cincinnati Children’s cares for kids in the city and region as well as children who come from across the country and outside the U.S. borders. It is a leader in research, as well, where Cancelas also leads translational research programs in cancer and blood diseases.
Additionally, Cincinnati Children’s ranks first in blood and platelet collections among hospital blood drive partners and was responsible for collecting 2,104 units of blood in 2022, making a significant impact for local patients like Brynn Schulte, who was diagnosed with Factor XIII shortly after she was born in 2019 and is being treated by Cincinnati Children’s. Factor XIII deficiency is an extremely rare blood disorder characterized by abnormal blood clotting that may result in abnormal bleeding.
"Brynn’s diagnosis is 1 in 5 million. She’s rare. Perfectly rare,” says Lindsay Schulte, Brynn's mother. “We are so thankful to Cincinnati Children’s, Hoxworth Blood Center and its donors, and the Tri-State Bleeding Disorder community for fiercely loving and supporting our Brynn.”
Cincinnati Children’s is hosting their next blood drive in the Sabin Auditorium on Friday, July 14. For more information and to schedule, visit https://hoxworth.org/groups/cchmc.html.
About Hoxworth:
Hoxworth Blood Center, University of Cincinnati, was founded in 1938, and serves more than 30 hospitals in 18 counties in Southwestern Ohio, Northern Kentucky and Southeastern Indiana. Annually, Hoxworth collects more than 100,000 units of blood from local donors to help save the lives of patients in area hospitals. Hoxworth Blood Center: Saving Lives Close to Home.
Related Stories
Chris Higgins named UC Foundation Vice President for Development, Academic Health Enterprise
January 6, 2026
The University of Cincinnati Foundation is pleased to welcome Chris Higgins as the new Vice President for Development, Academic Health Enterprise.
What's behind the mysterious rise of migraines?
January 5, 2026
Weather patterns such as extreme heat and storm conditions have been linked to migraine attacks, and research shows those environmental conditions are becoming more common. As National Geographic recently reported, one of the leading theories behind this mysterious rise is that climate change may be playing a role.
Top six 2025 nephrology drug approvals
January 5, 2026
“2025 has been a landmark year for kidney disease therapeutics, marked by a comprehensive slate of FDA approvals covering endothelin-receptor blockade, complement inhibition, GLP-1-based metabolic protection, and B-cell-directed therapy,” Prakash Gudsoorkar, MD, associate professor of clinical medicine at the University of Cincinnati College of Medicine and staff nephrologist at UC Health, recently told MedCentral.